The transcriptional programs regulated through the activity of the androgen receptor (AR) modulate normal prostate development and the maintenance of prostatic functions at maturity.
AR signaling also controls key survival and growth functions operative in prostate cancer. Inhibiting the AR program remains the key target in the treatment of advanced prostate cancer, and suppressing AR also holds great potential for preventing the development or progression of early stage prostate cancer. In this review, we detail molecular mechanisms of AR activity, cellular components contributing to the maintenance of AR signaling despite AR-ligand suppression, and discuss treatment strategies designed to target components of resistance to AR-directed therapeutics.
Written by:
Green SM, Mostaghel EA, Nelson PS. Are you the author?
Divisions of Human Biology, Fred Hutchinson Cancer Research Center, Seattle WA, United States.
Reference: Mol Cell Endocrinol. 2012 Mar 20. Epub ahead of print.
doi: 10.1016/j.mce.2011.09.046
PubMed Abstract
PMID: 22453214
UroToday.com Prostate Cancer Section